Belite Bio up on finalizing late-stage eye drug study design
18/11/2022 15:29
** Belite Bio Inc BLTE.O shares up 3.3% at $26.9
** Drug developer says it has finalised the design of a
late-stage study for evaluating the efficacy of its treatment
for eye disorder, following discussions with the U.S. FDA
urn:newsml:reuters.com:*:nGNX2dK5Qd
** Co expects to begin enrolling patients in the study by H1
2023
** Including session gains, BLTE stock has more than doubled
since its IPO in April
Recent news on Belite Bio
See all newsBrief: Belite Bio Announces Uplisting To The Nasdaq Global Select Market
Brief: Belite Bio Announces Multi-Market Submission Of Marketing Authorization Applications Via The Access Consortium Pathway For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Brief: Belite Bio Announces Submission Of New Drug Application To The Ministry Of Health, Labour, And Welfare In Japan Under The Sakigake Designation System For Tinlarebant For The Treatment Of Stargardt Disease Type 1
Belite Bio, Inc reports results for the quarter ended June 30 - Earnings Summary
Belite Bio Q2 net loss widens on higher expenses